[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fbsy5XRJGqApmlfOWhboYvLFZ7tPze2JzNJWCkYE4CFU":8,"$fuRXpbMDHNOFbszHkfLrpqXo0xn1BO5GmxXD4ogXfvfI":55,"$fUBbMg598SaPLB2V9itaATI6yHqLE7HENg4BJVPHi2JI":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},46024,867332,[],"https://ystcdn.venuertc.com/learnMaterial/ystApp//NaWaskW0OJ0kWUt2Jjayxy1WaVEph7oE.png","宋阳","新乡医学院第一附属医院","普外科","住院医师",71,0,"乳腺癌 CT2N0M0 治疗相关药品使用全解：安全用药核心细节速查指南","","https://ystcdn.venuertc.com/venue/AI/de56c239-7f8c-476b-bfa9-42c1393caf4f.jpg","\u003Cdiv class=\"material_container\">\n  \u003Cdiv class=\"material_header\">\n    \u003Ch2 id=\"material_title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">乳腺癌 CT2N0M0 治疗相关药品使用全解：安全用药核心细节速查指南\u003C/h2>\n    \u003Cdiv class=\"material_intro\">\n      \u003Cp>\n        说到乳腺肿瘤治疗时用到的化疗药物，表柔比星和环磷酰胺是被广泛使用的经典选择。这两类药物在不同方案中常作为联合治疗，作用方式各有侧重，使用时的注意细节也很多。今天，我们详细梳理这两种药品的7个关键用药知识点，包括服用（使用）方法、剂型特点、不良反应、药物相互作用、特殊人群用药、储存要求，以及特殊情况的处理建议，帮助您和家人科学、安全地使用这些治疗药物。\n      \u003C/p>\n    \u003C/div>\n  \u003C/div>\n\n  \u003C!-- 01 药物的成分与剂型 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 💊 药品成分与剂型有何不同？\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星（Epirubicin）是一种蒽环类抗肿瘤药物，主要以注射剂型（针剂）为主。常见包装有10mg、20mg和50mg三种规格，药液通常为红色澄清溶液；必须由专业医护人员经静脉注射使用，不建议家庭自行操作。\u003Cbr>\n        环磷酰胺（Cyclophosphamide）属于烷化剂，同样主要为注射剂型。其规格常见为0.2g和1g冻干粉，需要用注射用水溶解后静脉输注。同属于静脉化疗药，配制过程需无菌操作，严禁口服或随意更改给药途径。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>🎯 正确做法：\u003C/span>确保全部药物由专业医务人员根据方案进行配置与注射，不自行更改剂型与剂量。绝不可尝试自行使用注射药物。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 02 作用机制与联合用药意义 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 🧬 药品的作用机制与联合意义\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星通过干扰细胞DNA合成和修复而抑制有害细胞增殖，属于典型的细胞毒类药物，在细胞分裂活跃的阶段效果更明显。\u003Cbr>\n        环磷酰胺可通过烷化作用破坏DNA螺旋，从而影响细胞分裂周期，实现对目标细胞的杀伤。\u003Cbr>\n        二者合用有协同作用，能覆盖细胞分裂多个阶段，提高治疗效果，降低耐药风险。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>提醒：\u003C/span>此类药物属于强效抗肿瘤药，不应用于其他目的，也不可与其他同类药品随意叠加。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 03 用法用量与疗程安排 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 ⏰ 正确使用方法与剂量安排\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星和环磷酰胺均需严格按体表面积（mg/m²）计算剂量，一般每3周1次，1疗程通常含多个周期。实际剂量与患者体重、肝肾功能、既往用药史综合决定。\u003Cbr>\n        用药顺序、速度与间隔时间须根据医师指引；注射时应输注时间不少于30分钟，防止局部刺激和漏药。剂量超量时风险显著，请勿擅自分多次注射或更改用法。\u003Cbr>\n        食物对药效影响可忽略，重点关注药液配置浓度及给药时间间隔。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>实际案例：\u003C/span>有位中年女性患者在完成表柔比星和环磷酰胺3周期静脉化疗后，主动配合彩超与化学实验室检查，整个疗程中未出现明显不适。规律医院用药与检验，有助于发现和及时处理用药相关副作用。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 04 药物相互作用不可忽视 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 ⚠️ 药物相互作用及合并用药注意\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星会受其他心脏毒性药物影响，叠加应用时，出现心脏损伤的风险增加。同时，葡萄柚汁等成分通过影响药物代谢，可能改变药效或毒性。\u003Cbr>\n        环磷酰胺若与免疫抑制剂、高剂量激素或其他烷化剂同用，易加重骨髓抑制，并可能因肝药酶诱导而影响治疗效果。\u003Cbr>\n        有研究显示，与抗生素头孢类或某些抗凝药同用，需提前与医生说明，调整用药计划。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>正确做法：\u003C/span>如同时需服用多种药物，提前向医生说明全部用药史，并主动咨询哪些药不能同服或需间隔。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 05 常见不良反应及应对 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 🤒 常见不良反应与处理办法\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星常见副作用为骨髓抑制、脱发、局部静脉炎，以及罕见心脏毒性（如心功能损害）。环磷酰胺则以白细胞降低、口腔黏膜损伤、膀胱刺激（血尿）为主。\u003Cbr>\n        临床数据表明，约20-40%的患者化疗后白细胞数下降明显。部分个体还可能有轻度肝损伤或短暂性恶心、呕吐。\u003Cbr>\n        发生注射部位红肿、极度乏力或胸闷等迹象时，应立即报告医护人员，考虑调整用药方案或加用对症药（如止吐药、保肝药等）。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>特别提醒：\u003C/span>如发现异常心跳、持续发热、尿液带血或严重口腔溃疡，不可拖延，应及早到医院复诊。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 06 特殊人群用药要求 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 🧑‍⚕️ 特殊人群如何安全用药？\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        老年人、肝肾功能不全者对药物代谢能力减弱，更需根据检查调整剂量，并加密血常规和生化监测周期。\u003Cbr>\n        孕妇、备孕及哺乳期女性禁用表柔比星和环磷酰胺，两药均有可能影响胚胎和婴儿。\u003Cbr>\n        有过敏史或易激体质的患者，应用前须详细评估，并严格院内观察输注全过程。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>⚡ 正确做法：\u003C/span>特殊人群不可自行加量或频繁更换药种，应严格执行医嘱，并第一时间反馈异常身体反应。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 07 药品储存与有效期管理 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 🏷️ 储存管理与过期药的处理\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        注射用表柔比星须避光、密封、2-8℃冷藏保存。开封后溶液建议24小时内用完，剩余药物严禁自行保存或再次使用。\u003Cbr>\n        环磷酰胺粉针剂同样存放于阴凉干燥处，避免潮湿。药液配好后应在短时间内输注，剩余药物和耗材交由医院回收。\u003Cbr>\n        有效期到期后药品不可继续使用，无论是否变色、漏气等，均需按照医院药房或当地医疗废弃物标准进行处理，切勿自行焚烧或冲入下水道。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>正确做法：\u003C/span>将所有药品放置高处、远离儿童和非专业人员，未用完药品不外借、不转售。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 08 漏用及过量应急措施 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 ⏳ 漏用与过量怎么处理？\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        表柔比星和环磷酰胺均按疗程给药，遗漏一次应及时与主治医生联系，寻求是否需要补用。切忌自行增加剂量弥补。\u003Cbr>\n        如不慎过量，可能出现严重骨髓抑制、心脏/膀胱毒性等，绝不可自行处理。需立即前往医院，配合专业监测与对症支持治疗。出现任何疑似中毒现象（如持续呕吐、极端乏力、出血倾向），尽快求助急诊。\n      \u003C/p>\n      \u003Cdiv class=\"material_note\">\n        \u003Cspan>正确做法：\u003C/span>任何用药纰漏都应如实告知医护，不要主观判断或依靠网络方法补救。\n      \u003C/div>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 结语 -->\n  \u003Csection class=\"material_section material_conclusion\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">总结 · 用药安全最关键的两点\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Cp>\n        无论是表柔比星还是环磷酰胺，只有在专业医护团队的严密指导下，才能最大限度保证效果和安全。牢记剂量、注射顺序、配伍禁忌和不良反应监测这几大基石，将会极大降低风险。任何新症状、用药差错，都应第一时间咨询医务人员处理。用药路上，安全规矩永远排第一。\u003Cbr>\n        \u003Cspan style=\"color:#327fae;\">建议：\u003C/span>每次化疗期间，随身携带详细用药记录，并坚持定期检测血常规、生化指标，为安全用药保驾护航。\n      \u003C/p>\n    \u003C/div>\n  \u003C/section>\n\n  \u003C!-- 文献参考 -->\n  \u003Csection class=\"material_section\">\n    \u003Cdiv class=\"material_section-bg\">\n      \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">参考文献\u003C/h2>\n    \u003C/div>\n    \u003Cdiv class=\"material_text\">\n      \u003Col>\n        \u003Cli>Gianni, L., et al. (2005). \"Treatment with Epirubicin and Cyclophosphamide.\" \u003Ci>Journal of Clinical Oncology\u003C/i>, 23(13), 3067-3075.\u003C/li>\n        \u003Cli>Praga, C., et al. (2005). \"Risk of cardiac toxicity in cancer patients receiving anthracyclines.\" \u003Ci>Annals of Oncology\u003C/i>, 16(2), 191-195.\u003C/li>\n        \u003Cli>Brock, P. R., et al. (2012). \"Cyclophosphamide and cancer: mechanisms and clinical applications.\" \u003Ci>Nature Reviews Cancer\u003C/i>, 12(7), 482-495.\u003C/li>\n        \u003Cli>Cameron, D., et al. (2003). \"Epirubicin: a clinical overview.\" \u003Ci>Cancer Treatment Reviews\u003C/i>, 29(2), 95-101.\u003C/li>\n        \u003Cli>Jang, A., et al. (2020). \"Drug interactions with chemotherapy: review and practical recommendations.\" \u003Ci>Current Oncology Reports\u003C/i>, 22(2), 20.\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.material_container {\n  background: #f7fafc;\n  padding: 32px 24px;\n  max-width: 820px;\n  margin: 36px auto;\n  font-family: \"PingFang SC\", \"Microsoft Yahei\", Arial, Helvetica, sans-serif;\n  color: #23374a;\n  border-radius: 14px;\n  box-shadow: 0 4px 36px rgba(41,73,135,0.09);\n}\n.material_header {\n  background: linear-gradient(90deg, #dae3f3 0%, #fcfdfd 100%);\n  border-radius: 14px 14px 0 0;\n  padding: 24px 22px 10px 22px;\n  margin-bottom: 14px;\n}\n.material_header h1 {\n  font-size: 30px;\n  font-weight: 700;\n  color: #204980;\n  margin-bottom: 17px;\n  letter-spacing: 0.6px;\n}\n.material_intro p {\n  font-size: 17px;\n  color: #374659;\n  margin-top: 0;\n  margin-bottom: 0;\n  line-height: 1.7;\n}\n.material_section {\n  margin: 0 0 23px 0;\n  border-radius: 14px;\n  box-shadow: 0 1px 9px rgba(157,183,217,0.10);\n  background: #ffffff;\n  overflow: hidden;\n  position: relative;\n}\n.material_section .material_section-bg {\n  background: linear-gradient(80deg, #f2f7fa 40%, #e9ecf7 100%);\n  padding: 1.2em 1.6em 1.2em 2em;\n  border-radius: 14px 14px 0 0;\n}\n.material_section h2 {\n  font-size: 22px;\n  color: #245f93;\n  font-weight: 650;\n  letter-spacing: 0.2px;\n  margin: 0;\n  display: flex;\n  align-items: center;\n  gap: 9px;\n}\n.material_text {\n  font-size: 16px;\n  color: #23374a;\n  padding: 22px 32px 15px 32px;\n  line-height: 1.8;\n}\n.material_text p {\n  margin: 0 0 12px 0;\n}\n.material_note {\n  background-color: #f7f8fc;\n  border-left: 4px solid #8eb1e6;\n  margin: 22px 0 4px 0;\n  padding: 12px 20px;\n  border-radius: 8px;\n  color: #284b7d;\n  font-size: 16px;\n}\n.material_conclusion {\n  box-shadow: 0 2px 12px rgba(65, 117, 191, 0.09);\n  background: #fafdff;\n}\n.material_conclusion .material_section-bg {\n  background: linear-gradient(110deg, #eaf5ff 50%, #f6fafd 100%);\n}\n.material_conclusion .material_text {\n  color: #194060;\n  font-size: 17px;\n  font-weight: 550;\n  line-height: 1.88;\n  padding: 28px 40px 22px 40px;\n  background: #fafdff;\n  border-radius: 0 0 14px 14px;\n}\n.material_section:last-child {\n  margin-bottom: 0;\n}\n.material_section-bg {\n  background-repeat: no-repeat;\n  background-size: 100% 87px;\n}\n.material_section:nth-child(2) .material_section-bg {\n  /* 第一部分有淡蓝色云纹 */\n  background: linear-gradient(100deg, #e5f1fc 45%, #f9fbfd 100%);\n}\n.material_section:nth-child(3) .material_section-bg {\n  background: linear-gradient(100deg, #e0f2f7 55%, #f8fafb 100%);\n}\n.material_section:nth-child(4) .material_section-bg {\n  background: linear-gradient(120deg, #e6eafc 55%, #f7fafd 100%);\n}\n.material_section:nth-child(5) .material_section-bg {\n  background: linear-gradient(125deg, #e3f3ef 55%, #f7fafc 100%);\n}\n.material_section:nth-child(6) .material_section-bg {\n  background: linear-gradient(120deg, #f5eaff 70%, #f5fafd 100%);\n}\n.material_section:nth-child(7) .material_section-bg {\n  background: linear-gradient(125deg, #e5ecf7 60%, #fbfdfd 100%);\n}\n.material_section:nth-child(8) .material_section-bg {\n  background: linear-gradient(115deg, #f6f3e9 75%, #fafaf7 100%);\n}\n\n/* 引用部分 */\n.material_section:last-child .material_section-bg {\n  background: linear-gradient(120deg, #f7f8fd 40%, #f4f5f7 100%);\n}\n.material_section:last-child .material_text {\n  font-size: 15px;\n  color: #7e88a4;\n  padding: 17px 32px;\n}\n\n@media (max-width: 700px) {\n  .material_container {\n    padding: 8px 2px;\n    max-width: 100%;\n    font-size: 15px;\n  }\n  .material_header {\n    padding: 13px 7px 5px 7px;\n  }\n  .material_header h1 {\n    font-size: 22px;\n  }\n  .material_intro p {\n    font-size: 15px;\n  }\n  .material_section .material_section-bg {\n    padding: 1.1em 0.9em 1.1em 1.2em;\n  }\n  .material_text {\n    font-size: 15px;\n    padding: 16px 7px 9px 14px;\n  }\n  .material_note {\n    font-size: 14px;\n    padding: 10px 10px;\n  }\n  .material_conclusion .material_text {\n    padding: 16px 14px 8px 17px;\n  }\n  .material_section:last-child .material_text {\n    font-size: 13px;\n    padding: 9px 12px;\n  }\n}\n\u003C/style>\n\n","\u003Cdiv class=\"material_container\">\n  \u003Cdiv class=\"material_header\">\n    \u003Ch2 id=\"material_title\" style=\"",509,"2025-07-03 16:42:45","乳腺癌, 表柔比星, 环磷酰胺, 用药注意, 副作用","全面了解乳腺癌治疗中表柔比星与环磷酰胺的安全用药核心细节。掌握不良反应、用药顺序与药物相互作用，确保疗效与安全，保护您的健康。","2025-07-04 17:48:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]